Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Susan E. Bates
Based on 7 articles published since 2009
(Why 7 articles?)
||||

Between 2009 and 2019, Susan Bates wrote the following 7 articles about Pancreatic Neoplasms.
 
+ Citations + Abstracts
1 Editorial Pancreatic Cancer: Challenge and Inspiration. 2017

Bates, Susan E. ·Columbia University Medical Center. ·Clin Cancer Res · Pubmed #28373360.

ABSTRACT: -- No abstract --

2 Editorial Pancreatic cancer: steps in the right direction. 2012

Bates, Susan E. · ·Clin Cancer Res · Pubmed #22896690.

ABSTRACT: -- No abstract --

3 Review Neoadjuvant Treatment for Pancreatic Cancer. 2019

Raufi, Alexander G / Manji, Gulam A / Chabot, John A / Bates, Susan E. ·The Division of Medical Oncology, Columbia University Medical Center, New York, NY. Electronic address: agr2139@cumc.columbia.edu. · The Division of Medical Oncology, Columbia University Medical Center, New York, NY. · The Department of Surgery, Columbia University Medical Center, New York, NY. ·Semin Oncol · Pubmed #30630600.

ABSTRACT: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with limited effective therapeutic options and exceedingly high mortality rates. Currently, cure can only be achieved through resection, however the vast majority of patients present with advanced disease for which upfront surgery is not an option. In an effort to improve surgical candidacy, neoadjuvant chemotherapy, with or without radiation therapy, is often used in an effort to downstage borderline resectable and locally advanced tumors, and some argue for its use even in patients with resectable tumors. Underlying this thinking is the recognition that pancreatic cancer is simultaneously both a locally invasive and systemic disease, even in patients without evidence of metastasis on imaging. Current evidence to date is largely retrospective, but suggests that neoadjuvant therapy can increase R0 (pathologically negative margin) resection rates and improve overall survival. The standard approach to neoadjuvant treatment involves choosing between the two most active combination regimens for metastatic disease, namely modified FOLFIRNOX and gemcitabine/nab-paclitaxel. Nonrandomized data indicate that these regimens can yield resection rates up to 68% and 36%, in borderline resectable and locally advanced PDAC, respectively. Furthermore, randomized data in patients with resectable PDAC treated with gemcitabine-based neoadjuvant therapy suggests that despite an approximate 10% drop in resection rates, there is a significant improvement in median overall survival. Herein, we will discuss the rationale for neoadjuvant therapy, current and former treatment regimens, common issues faced by clinicians when using these combinations, and several ongoing clinical trials.

4 Review Pancreatic Cancer: "A Riddle Wrapped in a Mystery inside an Enigma". 2017

Borazanci, Erkut / Dang, Chi V / Robey, Robert W / Bates, Susan E / Chabot, John A / Von Hoff, Daniel D. ·HonorHealth, Scottsdale, Arizona and TGen, Phoenix, Arizona. Erkut.Borazanci@HonorHealth.com. · Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania. · National Institutes of Health, Bethesda, Maryland. · Columbia University Medical Center, New York, New York. · James J. Peters Bronx VA Medical Center, Bronx, New York. · HonorHealth, Scottsdale, Arizona and TGen, Phoenix, Arizona. ·Clin Cancer Res · Pubmed #28373361.

ABSTRACT: Pancreatic ductal adenocarcinoma (PDAC) is one of the most difficult-to-treat cancers. With an increasing incidence and inability to make major progress, it represents the very definition of unmet medical need. Progress has been made in understanding the basic biology-systematic genomic sequencing has led to the recognition that PDAC is not typically a heavily mutated tumor, although there are exceptions. The most consistently mutated genes are

5 Article Clinical Trials in Pancreatic Cancer: A Long Slog. 2017

Enzler, Thomas / Bates, Susan. ·Division of Hematology and Oncology, Department of Medicine, Columbia University Medical Center, New York, New York, USA te2243@cumc.columbia.edu. · Division of Hematology and Oncology, Department of Medicine, Columbia University Medical Center, New York, New York, USA. ·Oncologist · Pubmed #28982802.

ABSTRACT: -- No abstract --

6 Article Pancreatic cancer: Targeting KRAS and the vitamin D receptor via microtubules. 2015

Basseville, Agnes / Bates, Susan / Fojo, Tito. ·Medical Oncology, Center for Cancer Research, National Cancer Institute, Building 10, Room 12N226, 9000 Rockville Pike, Bethesda, MD 20892, USA. ·Nat Rev Clin Oncol · Pubmed #26169922.

ABSTRACT: -- No abstract --

7 Minor Clinical trials: New drug for pancreatic cancer highlights the dual effect of regulatory approvals. 2016

Bates, Susan E / Fojo, Tito. ·Division of Hematology/Oncology, Department of Medicine, Columbia University Medical Center, Herbert Irving Pavilion, 9th Floor, 161 Fort Washington Avenue, New York, New York 10032, USA; and the James J. Peters VA Medical Center, 130 West Kingsbridge Road, Bronx, New York 10468, USA. ·Nat Rev Clin Oncol · Pubmed #26902963.

ABSTRACT: -- No abstract --